



ASX Release
4 May 2021

ASX Code: MEM

PROFFESOR JOHN AITKEN WINS 2021 DISTINGUISHED ANROLOGY AWARD

Memphasys is pleased to announce that the 2021 Distinguished Andrologist award has been granted to Laureate Professor John Aitken, University of Newcastle, by the American Society of Andrology¹ ("ASA").

Professor Aitken, who heads Memphasys' Scientific Advisory Committee, was formally recognized with the ASA's highest honor on April 24 for his scientific contributions to the field of andrology and his commitment to advancing the science of male reproductive health.

Using a combination of proteomic and biochemical approaches, John Aitken's research has elucidated the fundamental cellular and molecular mechanisms that regulate sperm function, fertilisation and early embryonic development. His group have identified various novel mediators of sperm-egg interaction, generating novel insights into the causes of human infertility as well as novel approaches to contraceptive development. They have also demonstrated that oxidative stress is heavily involved in the origins of defective mammalian sperm function, linking this pathway to DNA damage and providing a rational basis for anti-oxidant therapy in the male.

Professor Aitken and his research team have been collaborating with Memphasys to develop the Felix device for selection of healthy sperm for IVF procedures. More recently Professor John Aitken and his researchers have also been developing a portfolio of potential products focused on both human and animal reproduction, ranging from prospective novel medical devices and in vitro diagnostics to new, proprietary media.

In addition, a recent paper written by Professor John Aitken and Associate Professor Hassan Bakos, Scientific Director, Monash IVF, has been published in the prestigious "Human Reproduction" journal. This paper advocates routine assessment of DNA integrity in human spermatozoa in a clinical context particularly because oxidative sperm DNA damage plays a major role in determining the ultimate health and wellbeing of the offspring.

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
T: +61 2 8415 7300
E: alison.coutts@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
T: +0433 112 936
E: dtasker@chapteroneadvisors.com.au

¹ Andrology is the medical specialty that deals with male health, particularly relating to the problems of the male reproductive system and urological problems that are unique to men.

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Website: www.memphasys.com